1. Israel Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
IM Cannabis Corp.

IM Cannabis Corp.

IMCC.CN
IM Cannabis Corp.CA flagCanadian Securities Exchange
5.10
CAD
-3.40
- -
17.17MMarket Cap
IM Cannabis Corp.
IMCC.CN
(Canadian Securities Exchange)

Recent

price

5.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.03
23.98
35.66
45.39
22.84
23
21.75
Revenue per Share
-303.23
-233.37
-98.24
-73.58
-745.46
-28.1
-5.3
-1.83
-13.89
-3.31
-13.68
-43.3
-18.6
-157.8
-4.45
-4.51
-1.91
Basic EPS, GAAP
-255.53
-115.73
-315.58
-111.11
-68.43
-10.2
-3.09
- -
-10.69
-1.25
-14.08
-16.04
-40.8
-11.86
-4.05
-0.52
1.54
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3,641.5
-3,230.91
-2,789.39
-2,765.8
-3,456.07
-3,094.85
-1,971.86
1,073.23
1,024.16
-65.57
40.67
6.09
195.74
5.18
2.22
2.58
2.54
Book Value per Share
1,362.95
1,712.04
1,412.3
1,336.26
-21.96
-36.06
-48.34
-50.17
-50.78
-5.79
46.76
16.92
55.24
5.11
-1.03
-2.92
-2.55
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
2
3
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9
16
34
54
49
54
54
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-73.21
-51.89
-67.64
-41.42
-24.95
-18.94
-13.22
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
6
7
3
2
2
Depreciation Expense
-1
-1
-1
-1
-5
- -
- -
- -
- -
- -
-7
-29
-18
-189
-9
-11
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-80.36
-180.6
-52.16
-347.64
-19.46
-19.59
-8.79
Profit Margin (%)
1
2
- -
- -
- -
- -
- -
- -
- -
- -
22
21
30
-1
-9
-12
-11
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
18
1
1
1
1
LT Debt
6
10
10
9
- -
- -
- -
- -
- -
- -
26
13
205
24
14
3
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-1.35
- -
- -
-223.22
-18.6
-195.6
-173.65
-196.05
-203.41
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
15
17
15
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
3
Market Capitalization
7
7
6

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
28
23
30
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
14
14
17
Inventories
4
3
5
Total Current Liabilities
39
35
41
Payables & Accruals
24
15
16
ST Debt
15
17
15
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1,099.94%
253.14%
-77.04%
Free Cash Flow
- -
23.97%
-85.76%
Net Income, GAAP
752.59%
227.06%
11.44%
Sales/Revenue/Turnover
- -
49.9%
10.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
13
13
12
11
49
2024
12
15
14
13
54
2025
12
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.4
-1.56
-0.96
- -
-4.45
2024
-2.52
-1.38
-0.41
- -
-4.51
2025
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
RPG Life Sciences Limited (RPGLIFE.BO)
Torii Pharmaceutical Co., Ltd. (TRXPF)
HUTCHMED (China) Limited (0013.HK)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
Enorama Pharma AB (publ) (ERMA.ST)
Alkem Laboratories Limited (ALKEM.NS)
Business
IM Cannabis Corp. engages in the breeding, cultivation, processing, importation, distribution, and sale of premium medical cannabis products primarily to patients in Israel and Germany. The company offers dried cannabis flowers, full-spectrum strain-specific extracts, pre-rolls, and related products under the IMC, BLKMT, WAGNERS, and LOT420 brands; it also provides cannabis fulfillment services through its EU-GMP licensed packing facility and GDP logistics center in Germany via subsidiary Adjupharm GmbH. In Israel, operations include medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs conducted through a commercial relationship with Focus Medical Herbs Ltd., leveraging proprietary patient data and a vertically integrated supply chain for quality control and delivery. Founded in 2008 and headquartered in Glil Yam, Israel, IM Cannabis targets medical patients in two of the largest regulated medical cannabis markets and recently exited its Canadian adult-use operations, including Trichome Financial Corp. and brands such as WAGNERS and Highland Grow, to focus resources on sustainable growth in Israel and Germany. Recent developments include a July 2025 USD 1 million loan agreement with L.I.A. Pure Capital Ltd., bearing 8% annual interest with potential for an additional USD 1 million and a commitment to raise at least USD 3 million via an underwritten offering, alongside the appointment of pharmaceutical executive Oz Adler to its board of directors; in October 2025, the company signed a non-binding term sheet to acquire a 60% stake in a quantum computing bio data company for up to USD 54 million in aggregate consideration.